Kodiak Sciences, a phase 1 biotech developing therapies for common ophthalmic diseases, raised $90 million by offering 9 million shares at $10, below the range of $13 to $15. Insiders purchased $58 million (64% of deal size) on the offering. At pricing, Kodiak will command a market value of $375 million. Kodiak Sciences plans to list on the Nasdaq under the symbol KOD. Morgan Stanley, BofA Merrill Lynch and Barclays acted as lead managers on the deal.
Kodiak Sciences prices IPO well below the range at $10
October 4, 2018

